![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Provides Update on Drisapersen
May 01, 2014 06:58 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, May 1, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, yesterday...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at the 66th Annual American Academy of Neurology (AAN) Annual Meeting and the 39th Annual Deutsche Bank Health Care Conference
April 28, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, April 28, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Appoint Michael Wyzga to Supervisory Board
April 08, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, April 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on rare diseases with a high
unmet medical need, today...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Announces Full Year 2013 Financial Results and Recent Corporate Developments
March 18, 2014 07:00 ET
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, March 18, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys
March 17, 2014 18:00 ET
|
Prosensa Holding N.V.
Chicago, IL, March 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch
biopharmaceutical company focusing on RNA-modulating therapeutics
for rare diseases with high unmet need,...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at Upcoming Investor Conferences
March 06, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, March 6, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) announced
today announced presentations at upcoming investor conferences.
Celia Economides, Senior...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Holding N.V. to Webcast Conference Call Discussing Full Year 2013 Financial Results and Corporate Update on March 18, 2014
March 05, 2014 10:18 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, March 5, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Tuesday, March 18,...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Participate at Upcoming Investor Conferences
January 31, 2014 09:16 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Jan. 31, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) announced
today that it is schedule to participate at the following investor
conferences in...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Reports Initial Findings from the Further Clinical Data Analyses of Drisapersen for the Treatment of Duchenne Muscular Dystrophy
January 16, 2014 12:35 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Jan. 16, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Provide Corporate Update to Key Stakeholders
January 13, 2014 15:09 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...